Tumor necrosis factor alpha is not implicated in the genesis of experimental autoimmune gastritis

Journal of Autoimmunity

Volumn 22, Issue 1, 2004, Pages 1-11

  Marshall, Aiden C J ^a   Toh, Ban Hock ^a   Alderuccio, Frank ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

Apoptosis; Autoimmunity; Stomach; TNF

Indexed keywords

TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; AUTOIMMUNE DISEASE; CELL DAMAGE; CELL DESTRUCTION; CELL INFILTRATION; CONTROLLED STUDY; EXPERIMENTAL AUTOIMMUNE GASTRITIS; GASTRITIS; HETEROZYGOSITY; MOLECULAR DYNAMICS; MONONUCLEAR CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; STOMACH PARIETAL CELL; TARGET CELL; THYMECTOMY; TRANSGENIC MOUSE;

EID: 0347989375     PISSN: 08968411     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaut.2003.09.003     Document Type: Article

References (52)

1. Allison J., Strasser A. Mechanisms of beta cell death in diabetes: a minor role for CD95. Proc Natl Acad Sci USA. 95:1998;13818-13822.
2. Benoist C., Mathis D. Cell death mediators in autoimmune diabetes - no shortage of suspects. Cell. 89:1997;1-3.
3. Feldmann M., Maini R.N. Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned? Annu Rev Immunol. 19:2001;163-196.
4. Taylor P.C. Anti-TNF therapy for rheumatoid arthritis and other inflammatory diseases. Mol Biotechnol. 19:2001;153-168.
5. Gleeson P.A., Toh B.H. Molecular targets in pernicious anaemia. Immunol Today. 12:1991;233-238.
6. Toh B.H., van Driel I.R., Gleeson P.A. Pernicious anaemia. N Engl J Med. 337:1997;1441-1448.
7. Martinelli T.M., van Driel I.R., Alderuccio F., Gleeson P.A., Toh B.H. Analysis of mononuclear cell infiltrate and cytokine production in murine autoimmune gastritis. Gastroenterology. 110:1996;1791-1802.
8. Alderuccio F., Toh B.H., Tan S.S., Gleeson P.A., van Driel I.R. An autoimmune disease with multiple molecular targets abrogated by the transgenic expression of a single autoantigen in the thymus. J Exp Med. 178:1993;419-426.
9. Suri-Payer E., Kehn P.J., Cheever A.W., Shevach E.M. Pathogenesis of post-thymectomy autoimmune gastritis: identification of anti-H/K adenosine triphosphate-reactive T cells. J Immunol. 157:1996;1799-1805.
10. D'Elios M.M., Bergman M.P., Azzurri A., Amedei A., Benagiano M., De Pont J.J., et al. H(+),K(+)-ATPase (proton pump) is the target autoantigen of Th1-type cytotoxic T cells in autoimmune gastritis. Gastroenterology. 120:2001;377-386.
11. Biondo M., Nasa Z., Marshall A., Toh B.H., Alderuccio F. Local transgenic expression of granulocyte macrophage-colony stimulating factor initiates autoimmunity. J Immunol. 166:2001;2090-2099.
12. Judd L.M., Gleeson P.A., Toh B.H., van Driel I.R. Autoimmune gastritis results in disruption of gastric epithelial cell development. Am J Physiol. 277:1999;G209-G218.
13. Beutler B., Bazzoni F. TNF, apoptosis and autoimmunity: a common thread? Blood Cells Mol Dis. 24:1998;216-230.
14. Wallach D., Varfolomeev E.E., Malinin N.L., Goltsev Y.V., Kovalenko A.V., Boldin M.P. Tumor necrosis factor receptor and Fas signaling mechanisms. Annu Rev Immunol. 17:1999;331-367.
15. Marshall A.C., Alderuccio F., Toh B.H. Fas/CD95 is required for gastric mucosal damage in autoimmune gastritis. Gastroenterology. 123:2002;780-789.
16. Pakala S.V., Chivetta M., Kelly C.B., Katz J.D. In autoimmune diabetes the transition from benign to pernicious insulitis requires an islet cell response to tumor necrosis factor alpha. J Exp Med. 189:1999;1053-1062.
17. Green E.A., Flavell R.A. Tumor necrosis factor-alpha and the progression of diabetes in non-obese diabetic mice. Immunol Rev. 169:1999;11-22.
18. Grewal I.S., Grewal K.D., Wong F.S., Picarella D.E., Janeway C.A. Jr, Flavell R.A. Local expression of transgene encoded TNF alpha in islets prevents autoimmune diabetes in nonobese diabetic (NOD) mice by preventing the development of auto-reactive islet-specific T cells. J Exp Med. 184:1996;1963-1974.
19. Christen U., Wolfe T., Mohrle U., Hughes A.C., Rodrigo E., Green E.A., et al. A dual role for TNF-alpha in type 1 diabetes: islet-specific expression abrogates the ongoing autoimmune process when induced late but not early during pathogenesis. J Immunol. 166:2001;7023-7032.
20. Selmaj K., Raine C.S., Cross A.H. Anti-tumor necrosis factor therapy abrogates autoimmune demyelination. Ann Neurol. 30:1991;694-700.
21. Selmaj K., Papierz W., Glabinski A., Kohno T. Prevention of chronic relapsing experimental autoimmune encephalomyelitis by soluble tumor necrosis factor receptor I. J Neuroimmunol. 56:1995;135-141.
22. Williams R.O., Feldmann M., Maini R.N. Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc Natl Acad Sci U S A. 89:1992;9784-9788.
23. Williams R.O., Mason L.J., Feldmann M., Maini R.N. Synergy between anti-CD4 and anti-tumor necrosis factor in the amelioration of established collagen-induced arthritis. Proc Natl Acad Sci U S A. 91:1994;2762-2766.
24. Butler D.M., Malfait A.M., Maini R.N., Brennan F.M., Feldmann M. Anti-IL-12 and anti-TNF antibodies synergistically suppress the progression of murine collagen-induced arthritis. Eur J Immunol. 29:1999;2205-2212.
25. Schadlich H., Ermann J., Biskop M., Falk W., Sperling F., Jungel A., et al. Anti-inflammatory effects of systemic anti-tumour necrosis factor alpha treatment in human/murine SCID arthritis. Ann Rheum Dis. 58:1999;428-434.
26. Feldmann M., Elliot M.J., Woody J.N., Maini R.N. Anti-tumor necrosis factor - a therapy of rheumatoid arthritis. Adv Immunol. 64:1997;283-350.
27. Escher J.C., Stoof T.J., van Deventer S.J., van Furth A.M. Successful treatment of metastatic Crohn disease with infliximab. J Pediatr Gastroenterol Nutr. 34:2002;420-423.
28. Scallon B., Caia A., Solowski N., Rosenberg A., Song X.Y., Shealy D., et al. Binding and functional comparisons of two types of tumor necrosis factor antagonists. J Pharmacol Exp Ther. 301:2002;418-426.
29. Peschon J.J., Torrance D.S., Stocking K.L., Glaccum M.B., Otten C., Willis C.R., et al. TNF receptor-deficient mice reveal divergent roles for p55 and p75 in several models of inflammation. J Immunol. 160:1998;943-952.
30. Alderuccio F., Toh B.H., Gleeson P.A., van Driel I.R. A novel method for isolating mononuclear cell from the stomachs of mice with experimental autoimmune gastritis. Autoimmunity. 21:1995;215-221.
31. +-ATPase complex by tomato-lectin affinity chromotography. Biochem J. 283:1992;63-68.
32. Alderuccio F., Sentry J.W., Marshall A.C., Biondo M., Toh B.H. Animal models of human disease: experimental autoimmune gastritis - a model for autoimmune gastritis and pernicious anemia. Clin Immunol. 102:2002;48-58.
33. Sakaguchi S., Toda M., Asano M., Itoh M., Morse S.S., Sakaguchi N. T cell-mediated maintenance of natural self-tolerance: its breakdown as a possible cause of various autoimmune diseases. J Autoimmun. 9:1996;211-220.
34. Suri-Payer E., Amar A.Z., Thornton A.M., Shevach E.M. CD4+CD25+ T cells inhibit both the induction and effector function of autoreactive T cells and represent a unique lineage of immunoregulatory cells. J Immunol. 160:1998;1212-1218.
35. Andre-Schmutz I., Hindelang C., Benoist C., Mathis D. Cellular and molecular changes accompanying the progression from insulitis to diabetes. Eur J Immunol. 29:1999;245-255.
36. Andre I., Gonzalez A., Wang B., Katz J., Benoist C., Mathis D. Checkpoints in the progression of autoimmune disease: lessons from diabetes models. Proc Natl Acad Sci U S A. 93:1996;2260-2263.
37. Campbell I.K., O'Donnell K., Lawlor K.E., Wicks I.P. Severe inflammatory arthritis and lymphadenopathy in the absence of TNF. J Clin Invest. 107:2001;1519-1527.
38. Mori L., Iselin S., De Libero G., Lesslauer W. Attenuation of collagen-induced arthritis in 55-kDa TNF receptor type 1 (TNFR1)-IgG1-treated and TNFR1-deficient mice. J Immunol. 157:1996;3178-3182.
39. Keating G.M., Perry C.M. Infliximab: an updated review of its use in Crohn's disease and rheumatoid arthritis. Biodrugs. 16:2002;111-148.
40. Brandt J., Haibel H., Reddig J., Sieper J., Braun J. Successful short term treatment of severe undifferentiated spondyloarthropathy with the anti-tumor necrosis factor-alpha monoclonal antibody infliximab. J Rheumatol. 29:2002;118-122.
41. Cohen R.D. Infliximab as first-line therapy for severe Crohn's disease? Inflamm Bowel Dis. 8:2002;58-59.
42. Feagan B.G., Enns R., Fedorak R.N., Panaccione R., Pare P., Steinhart A.H., et al. Infliximab for the treatment of Crohn's disease: efficacy, safety and pharmacoeconomics. Can J Clin Pharmacol. 8:2001;188-198.
43. Lugering A., Schmidt M., Lugering N., Pauels H.G., Domschke W., Kucharzik T. Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspase-dependent pathway. Gastroenterology. 121:2001;1145-1157.
44. Mortimore M., Gibson P.R., Selby W.S., Radford-Smith G.L., Florin T.H., Schering P. Early Australian experience with infliximab, a chimeric antibody against tumour necrosis factor-alpha, in the treatment of Crohn's disease: is its efficacy augmented by steroid-sparing immunosuppressive therapy? The Infliximab User Group. Intern Med J. 31:2001;146-150.
45. Steinfeld S.D., Demols P., Salmon I., Kiss R., Appelboom T. Infliximab in patients with primary Sjogren's syndrome: a pilot study. Arthritis Rheum. 44:2001;2371-2375.
46. Yang X.D., Tisch R., Singer S.M., Cao Z.A., Liblau R.S., Schreiber R.D., et al. Effect of tumor necrosis factor alpha on insulin-dependent diabetes mellitus in NOD mice. I. The early development of autoimmunity and the diabetogenic process. J Exp Med. 180:1994;995-1004.
47. Jacob C.O., Aiso S., Schreiber R.D., McDevitt H.O. Monoclonal anti-tumor necrosis factor antibody renders non-obese diabetic mice hypersensitive to irradiation and enhances insulitis development. Int Immunol. 4:1992;611-614.
48. McSorley S.J., Soldera S., Malherbe L., Carnaud C., Locksley R.M., Flavell R.A., et al. Immunological tolerance to a pancreatic antigen as a result of local expression of TNFalpha by islet beta cells. Immunity. 7:1997;401-409.
49. Sicotte N.L., Voskuhl R.R. Onset of multiple sclerosis associated with anti-TNF therapy. Neurology. 57:2001;1885-1888.
50. Frei K., Eugster H.P., Bopst M., Constantinescu C.S., Lavi E., Fontana A. Tumor necrosis factor alpha and lymphotoxin alpha are not required for induction of acute experimental autoimmune encephalomyelitis. J Exp Med. 185:1997;2177-2182.
51. TNF neutralization in MS: results of a randomized, placebo-controlled multicentrer study. Neurology. 53:1999;457-465.
52. Sarin A., Conan-Cibotti M., Henkart P.A. Cytotoxic effect of TNF and lymphotoxin on T lymphoblasts. J Immunol. 155:1995;3716-3718.